Dissualon – Dual potency, due to its triple mechanism of action, for the treatment of mixed dyslipidemia.


It is a treatment for hypercholesterolemia, which combines the action of Atorvastatin and Ezetimibe. Atorvastatin blocks the enzyme HMG-CoA Reductase, which is responsible for the synthesis of cholesterol in the body, while Ezetimibe inhibits the absorption of cholesterol in the intestine. It also causes a decrease in “bad cholesterol” or LDL-C and an increase in “good cholesterol” or HDL-C.

Mixed Dyslipidemia (DM) is a major risk factor for the development of Atherosclerosis. The most important marker of Atherosclerosis is coronary disease (CAD), one of the main causes of death in the world.